Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
chronic kidney disease
Biotech
Former Pfizer antibody reduces cardio risk marker in ph. 2
Pacibekitug, an antibody Tourmaline licensed from Pfizer in 2022, reduced levels of C-reactive protein in patients with chronic kidney disease.
Darren Incorvaia
May 20, 2025 7:30am
Novo to sue kidney disease drug maker for alleged fraud
Feb 18, 2025 3:00pm
2024's top 10 clinical trial flops
Feb 18, 2025 3:00am
Novo Nordisk discards $1.3B kidney drug in wake of phase 3 fail
Nov 6, 2024 4:54am
Otsuka's kidney disease drug improves UPCR levels in ph. 3 trial
Oct 22, 2024 10:38am
ProKidney halts ph. 3 trial not needed for cell therapy approval
Sep 3, 2024 8:55am
